Grants and Contracts Details
| Status | Active |
|---|---|
| Effective start/end date | 10/10/18 → 3/7/25 |
Funding
- Celgene International II Sarl: $135,766.00
Induction Study #1 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Sudy of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease
- Flomenhoft, Deborah (PI)